3 unknown, 2 completed, 2 recruiting, 2 terminated. 3 Phase 3, 2 Not applicable, 1 Early Phase 1, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Not applicable | 2 | Recruiting 1, Unknown 1 |
| Early Phase 1 | 1 | Terminated 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Low-molecular-weight heparin: new trials by email Literature Review of Low-molecular-weight heparin trials Research Report on Low-molecular-weight heparin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity Aspirin, Low-molecular-weight heparin - Venous Thromboembolism, Postpartum Period | Phase 3 | Recruiting | University of Calgary | 8805 | 2026-06-04 | 2026-07-27 |
| Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis Evolocumab 140 MG/ML [Repatha], Conventional lipid-lowering therapy - Hypertriglyceridemia Induced Acute Pancreatitis | Not applicable | Recruiting | General Hospital of Shenyang Military Region | 60 | 2026-01-02 | 2026-09-25 |
| D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia low-molecular-weight heparin - Coronavirus Disease (COVID)19 | Phase 4 | Unknown | Ain Shams University | 50 | 2020-08-01 | 2020-10-14 |
| AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study Aspirin 81 mg, Low-molecular-weight heparin - Antiphospholipid Syndrome in Pregnancy, Pregnancy Loss | Early Phase 1 | Terminated | Ottawa Hospital Research Institute | 1 | 2017-11-06 | 2020-04-08 |
| Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban rivaroxaban, Low-molecular-weight heparin - Neoplasm, Venous Thromboembolism | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 159 | 2016-09-01 | 2018-08-13 |
| Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients Rivaroxaban 10 MG, Rivaroxaban 20 MG, Low-molecular-weight heparin - Neoplasms | Phase 1 / Phase 2 | Completed | Capital Medical University | 74 | 2016-02-16 | 2019-04-16 |
| Rate of Venous Thrombosis in Acutely Ill Patients Hospitalized in Internal Medicine Wards low-molecular-weight heparin - Venous Thromboembolism, Deep Venous Thrombosis | Unknown | University of Roma La Sapienza | 1000 | 2015-02-01 | 2017-05-17 | |
| Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis Low-Molecular-Weight Heparin - Deep Venous Thrombosis | Not applicable | Unknown | University of Tennessee | 100 | 2010-02-01 | 2011-06-16 |
| Tapered Warfarin or Interrupted Warfarin With Heparin Bridging for Pacemaker or Defibrillator Implantation Tapered warfarin regimen, Bridged regimen Low-molecular-weight heparin - Cardiac Arrhythmias, Hemorrhage | Phase 3 | Terminated | McMaster University | 173 | 2007-12-01 | 2016-04-05 |
Venous Thromboembolism (4) · Venous Thrombosis (3) · Neoplasms (2) · Arrhythmias, Cardiac (1) · Atrial Fibrillation (1) · COVID-19 (1) · Hemorrhage (1) · Postpartum Hemorrhage (1) · Pre-Eclampsia (1) · Pulmonary Embolism (1) · Stroke (1) · Thromboembolism (1) · Thrombophilia (1)
Ain Shams University (1) · Assistance Publique - Hôpitaux de Paris (1) · Capital Medical University (1) · General Hospital of Shenyang Military Region (1) · McMaster University (1) · Ottawa Hospital Research Institute (1) · University of Calgary (1) · University of Roma La Sapienza (1) · University of Tennessee (1)
Canada (3) · China (2) · France (2) · Belgium (1) · Denmark (1) · Egypt (1) · Ireland (1) · Italy (1) · Netherlands (1) · Poland (1) · United States (1)
Leslie Skeith, MD (2) · Marc Rodger, MD (2) · Ashraf Madkour (1) · Dale Ingram, M.D. (1) · Francesco Violi, MD (1) · Guy Meyer, MD (1) · Lorenzo Loffredo, MD (1) · Sam Schulman, MD, PhD (1)
PMID 25127655, PMID 30903459, PMID 32358837, PMID 34172290, PMID 34627853, PMID 35244208, PMID 36451162